TIAM2 Contributes to Osimertinib Resistance, Cell Motility, and Tumor-Associated Macrophage M2-like Polarization in Lung Adenocarcinoma

Background: Osimertinib-based therapy effectively improves the prognosis of lung adenocarcinoma (LUAD) patients with epidermal growth factor receptor mutations. However, patients will have cancer progression after approximately one year due to the occurrence of drug resistance. Extensive evidence ha...

Descripción completa

Detalles Bibliográficos
Autores principales: Liang, Lu, He, Hua, Jiang, Shiyao, Liu, Yueying, Huang, Jingjing, Sun, Xiaoyan, Li, Yi, Jiang, Yiqun, Cong, Li
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9499457/
https://www.ncbi.nlm.nih.gov/pubmed/36142328
http://dx.doi.org/10.3390/ijms231810415

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9499457/
https://www.ncbi.nlm.nih.gov/pubmed/36142328
http://dx.doi.org/10.3390/ijms231810415

Ejemplares similares